Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours
Open Access
- 1 January 2001
- journal article
- review article
- Published by Elsevier BV in Annals of Oncology
- Vol. 12 (suppl_2), S95-S99
- https://doi.org/10.1093/annonc/12.suppl_2.s95
Abstract
Gastroenteropancreatic (GEP) neoplasms originate from any of the various cell types belonging to the neuroendocrine system. A general characteristic of GEP endocrine tumours is that the vast majority produce and secrete a multitude of peptide hormones and amines. Many patients with malignant metastasising tumours present clinical symptoms related to hormone hyperproduction. These include the so-called carcinoid syndrome, characterised by flushing, diarrhoea, wheezing and right heart disease, which is predominantly associated with the serotonin-and tachykinins-producing carcinoids of the midgut. Several types of syndrome associated with GEP endocrine tumors are caused by overproduction of a specific hormone. For instance, the well-known Zollinger-Ellison syndrome is gastrin-mediated. The so-called ‘insulinoma syndrome’ depends on excessive production of insulin and proinsulin, resulting in hypoglycemia. The ‘glucagonoma syndrome’ is characterised by necrolytic migratory erythema, diabetes and diarrhoea. The Verner-Morrison syndrome, which is brought about by high circulating levels of vasointestinal peptide (VIP), produces severe secretory diarrhoea. Finally the ‘somatostatinoma syndrome’ involves gallbladder dysfunction and gall stones, diarrhoea with or without steatorrhea, and impaired glucose tolerance. The biochemical diagnosis of endocrine digestive tumors is based on general and specific markers. The best general markers are chromogranin A (CgA) and pancreatic polypeptide (PP). Specific markers for endocrine tumors include insulin, gastrin, glucagon , vaso intestinal polypeptide (VIP), somatostatin and the primary cathabolic product of serotonin, 5-hydroxyndoleacetic acid (5-HIAA). Localisation procedures commonly applied, in the diagnosis of endocrine tumours include ultrasound (US), computed tomography (Cl and somatostatin receptor scintigraphy (SRS).This publication has 10 references indexed in Scilit:
- Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974–97British Journal of Cancer, 2000
- An analysis of 8305 cases of carcinoid tumorsCancer, 2000
- Tumor Markers in Neuroendocrine TumorsDigestion, 2000
- Neuroendocrine gastrointestinal tumors - A condensed overview of diagnosis and treatmentAnnals of Oncology, 1999
- The epidemiology of carcinoid tumours in England and ScotlandBritish Journal of Cancer, 1994
- Role of neuropeptides and serotonin in the diagnosis of carcinoid tumorsAmerican Journal Of Medicine, 1986
- Clinicopathological study of pancreatic and ganglioneuroblastoma tumours secreting vasoactive intestinal polypeptide (vipomas).BMJ, 1981
- Carcinoid TumorsAn analysis of 2837 casesCancer, 1975
- The carcinoid syndromeThe American Journal of Cardiology, 1968
- THE CLASSIFICATION OF CARCINOID TUMOURSThe Lancet, 1963